AstraZeneca was granted a patent for compounds targeting FAP-related conditions.

{
  "signal_id": "52abe794-1e3c-52fb-a455-a5394372c1a2",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-09-30T16:57:43+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07D 401/12"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Medical Research"
    ],
    "detail": "In September 2026 AstraZeneca patented quinoline carboxamide compounds for pharmaceutical use against conditions involving fibroblast activation protein, including potential diagnostic or treatment applications.",
    "summary": "AstraZeneca was granted a patent for compounds targeting FAP-related conditions.",
    "event_at": "2026-09-29",
    "inventors": [
      {
        "name": "Jonas Brånalt",
        "status": "resolved",
        "is_primary": true,
        "linkedin_url": "https://www.linkedin.com/in/jonas-br%C3%A5nalt-a374bb49"
      },
      {
        "name": "Maria Johansson",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Anneli Nordqvist",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/anneli-nordqvist-71b69b42"
      },
      {
        "name": "Gavin O'Mahony",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/gavin-o-mahony-bb498545"
      },
      {
        "name": "Marianne Swanson",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/marianne-swanson-39406948"
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-09-29",
    "source_url": "https://patents.google.com/patent/US12747223",
    "cpc_primary": {
      "code": "C07D 401/12"
    },
    "patent_title": "N-(2-(3-cyano-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)quinoline-4-carboxamides",
    "patent_number": "US12747223",
    "uspto_assignee": "AstraZeneca AB",
    "patent_abstract": "Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein R 2 , R 3 , R 5 , R 6 , R 7 , and R 8 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.",
    "precision_class": "structural",
    "invention_explanation": "A family of drug-like molecules designed to block FAP activity, with related formulations, manufacturing methods, and treatment uses.",
    "technologies_mentioned": [
      "medicinal chemistry",
      "small-molecule therapeutics",
      "FAP inhibitors",
      "pharmaceutical formulations"
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/52abe794-1e3c-52fb-a455-a5394372c1a2 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"astrazeneca.com","limit":20}'